USPTO Grants BetterLife's BETR-001 Composition of Matter Patent
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2025
0mins
Source: Newsfilter
Patent Approval: BetterLife Pharma Inc. has received a composition of matter patent for BETR-001, a non-hallucinogenic LSD derivative, ensuring its commercial potential and providing multiple layers of intellectual property protection.
Product Development Focus: The company is actively developing BETR-001 and BETR-002 to treat neuro-psychiatric disorders, with ongoing studies and additional patent applications aimed at expanding their treatment capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
